← Back to Home

First, Can the Antibody Reach the Tumor? HER3-Targeted Radiotherapy Begins a Pan-Cancer Imaging Trial

Actinium’s RADIANZ study has begun enrollment and, according to a company executive, the first patient has been dosed. PET tracking over up to two weeks will seek evidence to support expanding ATNM-400 into multiple solid cancers; this step measures drug distribution, while anticancer efficacy remains to be established.

By SURL BioNews

Before delivering a radioactive drug into a tumor, researchers must first answer a basic question: can the antibody guiding it reach the lesion and remain there long enough? Actinium Pharmaceuticals announced on November 11 that enrollment had begun in RADIANZ, an imaging trial supporting the development of HER3-targeted radiotherapy. The study will examine antibody distribution in humans to explore whether this strategy can extend beyond prostate cancer to other cancers.

The company announcement described the milestone as the start of enrollment, while Chairman and Chief Executive Officer Sandesh Seth stated in the same press release that the first patient had been dosed. The study includes patients whose disease has continued to progress after standard treatment, with cancer types including non-small cell lung cancer, breast cancer, colorectal cancer, pancreatic cancer and ovarian cancer. Imaging results from these patients have not yet been released.

RADIANZ uses the zirconium-89-labeled antibody formulation ⁸⁹Zr-barecetamab-DFO, tracking its movement through positron emission tomography (PET). Over an observation period of up to two weeks, researchers will assess the antibody’s distribution in tumors and other tissues, tumor uptake, changes in its concentration in the body and radiation doses to understand whether different cancer types meet the conditions for further development.

The therapeutic candidate supported by this imaging strategy is ATNM-400, or ²²⁵Ac-barecetamab-DOTA. It combines barecetamab, an antibody that recognizes HER3, with the alpha-particle-emitting isotope actinium-225, with the aim of delivering radiation to tumors. The imaging and therapeutic formulations use the same antibody but different radionuclides and chelators. PET findings can therefore provide clues for development, but cannot be directly equated with the therapeutic formulation’s actual distribution or cancer-killing effects.

ATNM-400 had previously entered a first-in-human Phase 1 trial in metastatic castration-resistant prostate cancer. According to preliminary data released by the company, the first three patients treated at a lower dose experienced no dose-limiting toxicities, and accompanying PET imaging showed that tumor uptake signals persisted through day seven. However, early observations in three patients are insufficient to establish safety, much less infer therapeutic benefit in other cancer types.

HER3 is associated with survival and treatment resistance in multiple solid cancers, providing a biological rationale for exploration across cancer types. However, the presence of a target and whether a drug can accumulate effectively are two questions that require separate validation. This announcement did not specify RADIANZ’s planned enrollment, allocation across cancer types or timeline for releasing results. The study’s immediate value is to provide evidence of distribution in humans for subsequent therapeutic trials. Whether treatment can shrink tumors, delay progression and deliver therapeutic doses that normal tissues can tolerate remains to be answered by subsequent clinical data.

References

  1. PR Newswire
  2. Actinium Pharmaceuticals, Inc.